Director's Shareholding

RNS Number : 8479I

Hutchison China Meditech Limited

04 June 2014

 



Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Director's Shareholding

London: Wednesday, 4 June 2014: Chi-Med received notification on 3 June 2014 that Mr Christopher Nash, Independent Non-executive Director of Chi-Med, purchased 4,036 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP8.42 each on
3 June 2014.

Following this purchase, Mr Nash is beneficially interested in 30,542 Shares, representing approximately 0.06% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med     Christian Hogg, CEO	Telephone:      [phone]
Panmure Gordon (UK) Limited     Richard Gray     Andrew Potts	Telephone:      [phone]
Citigate Dewe Rogerson     Anthony Carlisle     David Dible	Telephone:      [phone] Mobile:             [phone] Mobile:             [phone]

 

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med (LSE:HCM) is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

 

END

 

 

MSCSSFFELFLSEIM